Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023)

Historic Current Deferred Revenue for Q32 Bio (QTTB) over the last 7 years, with Q1 2023 value amounting to $354000.0.

  • Q32 Bio's Current Deferred Revenue fell 8896.51% to $354000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $354000.0, marking a year-over-year decrease of 8896.51%. This contributed to the annual value of $1.2 million for FY2022, which is 6396.51% down from last year.
  • According to the latest figures from Q1 2023, Q32 Bio's Current Deferred Revenue is $354000.0, which was down 8896.51% from $1.2 million recorded in Q4 2022.
  • In the past 5 years, Q32 Bio's Current Deferred Revenue registered a high of $5.6 million during Q4 2020, and its lowest value of $354000.0 during Q1 2023.
  • Over the past 5 years, Q32 Bio's median Current Deferred Revenue value was $1.3 million (recorded in 2019), while the average stood at $2.2 million.
  • As far as peak fluctuations go, Q32 Bio's Current Deferred Revenue surged by 56976.74% in 2021, and later crashed by 8896.51% in 2023.
  • Over the past 5 years, Q32 Bio's Current Deferred Revenue (Quarter) stood at $1.3 million in 2019, then skyrocketed by 328.94% to $5.6 million in 2020, then crashed by 43.04% to $3.2 million in 2021, then plummeted by 63.97% to $1.2 million in 2022, then plummeted by 69.38% to $354000.0 in 2023.
  • Its last three reported values are $354000.0 in Q1 2023, $1.2 million for Q4 2022, and $2.0 million during Q3 2022.